Fortrea Holdings (FTRE) Net Cash Flow Growth (1y) (2023 - 2026)
Fortrea Holdings (FTRE) Net Cash Flow Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | 53.46% |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | -26.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.90% |
| Dec 31, 2025 | 135.38% |
| Sep 30, 2025 | 304.49% |
| Jun 30, 2025 | -170.37% |
| Mar 31, 2025 | -45.93% |
| Dec 31, 2024 | 1,047.06% |
| Sep 30, 2024 | -690.32% |
| Jun 30, 2024 | 485.71% |
| Mar 31, 2024 | -314.29% |
| Dec 31, 2023 | 312.50% |
| Sep 30, 2023 | -117.71% |